TP53 and hypoparathyroidism-retardation-dysmorphism syndrome: The Ovarian Serous Cystadenocarcinoma TCGA PanCancer Atlas dataset contained mutation-level data for 409 cases, which included 373 (91.2%) tumors harboring pathogenic alterations in TP53. For subgroup and survival analyses, we abstracted data for TCGA cases with HR scores reported by Takaya et al. that also had mRNA expression data available23, producing an experimental cohort of 272 cases consisting of 150 (55.1%) HRP and 122 (44.9%) HRD tumors (Supplemental Table 1).